Biolidics Limited (SGX: 8YY)

Market Cap	7.75M
Revenue (ttm)	1.28M
Net Income (ttm)	-2.99M
Shares Out	774.76M
EPS (ttm)	-0.00
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	402,800
Open	n/a
Previous Close	n/a
Day's Range	n/a
52-Week Range	0.0080 - 0.0180
Beta	n/a
Analysts	n/a
Price Target	n/a
Earnings Date	Nov 13, 2024

About Biolidics

Biolidics Limited, a precision medicine medical technology company, focuses on developing a portfolio of diagnostic solutions. The company operates through Cancer, Infectious Diseases, and Laboratory Services segments. It provides Covid-19 PCR testing kits. The company offers ClearCell FX1 System, an automated device that separates and enriches cancer cells from blood; and antigen and antibody test kits, as well as laboratory services. It serves academic and research institutes, hospitals, and laboratories in Singapore, China, Hong Kong, Japan,...

• Industry: Electromedical and Electrotherapeutic Apparatus
• Founded: 2009
• Employees: 15
• Stock Exchange: Singapore Exchange - Catalist
• Ticker Symbol: 8YY

Financial Performance

In 2023, Biolidics's revenue was 1.36 million, a decrease of -48.85% compared to the previous year's 2.66 million. Losses were -2.49 million, -73.46% less than in 2022.